- Home
- Equipment
- united kingdom
- phase 1 clinical
Refine by
Phase 1 Clinical Equipment Supplied In United Kingdom
12 equipment items found
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB002 is an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of Acute Myeloid Leukaemia (AML). This product is currently undergoing a phase 1 clinical trial as part of a dose escalation and safety study, in partnership with ÚKHT, Institute of Hematology and Blood Transfusion, Prague. AML is a cancer ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. Phase 1 clinical study is completed to confirm the predictions in patients with metastatic colorectal cancer (NCT03391232, Hubbard et al ASCO 2020). ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
Background to the NTCD-M3 Clostridioides difficile Programme. NTCD-M3 was developed by GI infection physician, Professor Dale Gerding, who is a world-leading specialist in C. difficile, with more than 400 peer-reviewed journal publications, book chapters and review articles in the area. NTCD-M3 has successfully completed Phase 1 and Phase 2b trials with NTCD-M3. The Phase 1 study demonstrated a ...
Manufactured by:SpyBiotech Limited based inOxford, UNITED KINGDOM
CMV is the most common virus that most people have never heard of, even though it has now been identified as a high priority for vaccines development by key authorities such as the FDA and Institute of ...
Manufactured by:Exscientia based inOxford, UNITED KINGDOM
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Scancell’s lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from the cloning of T cells from patients who achieved spontaneous recovery from melanoma skin cancers. Both proteins play key roles in the production of melanin in the ...
Manufactured by:Invicro, LLC based inNeedham, MASSACHUSETTS (USA)
Invicro has spent 20 years specializing in neuroscience imaging solutions for preclinical, early phase and late phase clinical studies. Our capabilities span from in vitro assays to in vivo imaging using PET, SPECT and MRI imaging biomarkers in CNS drug development and CNS clinical trials. We have expertise in coordinating worldwide multi-center imaging studies, and providing management and ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
A Phase 2b clinical study, which was a multi-centre, randomized, placebo-controlled study of XF-73 nasal gel as a new product for the prevention of the incidence of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA) completed recruitment at the end of 2020 and top-line results were reported in Q1 2021, as ...
Manufactured by:Avelas Biosciences based inLa Jolla, CALIFORNIA (USA)
Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is designed to deliver a fluorescent marker specifically to cancer cells to enable surgeons to identify cancerous tissue in real-time and thus, avoid repeat surgeries and improve patient outcomes. Pegloprastide is the only fluorescence-based clinical cancer detection product that uses the ratio of two ...
Manufactured by:The Electrospinning Company Ltd. based inDidcot, UNITED KINGDOM
Cornea Regeneration on a synthetic membrane with limbal tissue explants. The University of Sheffield, in collaboration with the L.V.Prasad eye clinic in Hyderabad, developed corneal repair materials and procedures that offer a step change in availability and affordability. Phase I clinical trials have demonstrated patient safety. ...